Website
Now part of www.leo-pharma.com
Peplin was a biotechnology company focused on developing topical dermatological treatments for pre-cancerous skin lesions.
Peplin’s lead product, PEP005 (ingenol mebutate), is a topical gel that treats actinic keratosis with short-duration application. It induces rapid lesion clearance through a novel mechanism of action involving cell death and immune stimulation.
The company was acquired Leo Pharma for $US287.5M in 2009.
Read more about the acquisition: https://www.fiercebiotech.com/biotech/leo-pharma-to-acquire-peplin-for-us-287-5m